The authors review the current regulatory framework for the selection of drug substance starting materials.
Graham Illing
Advertisement
Graham T. Illing, PhD, is a CMC director and group manager of global regulatory affairs at AstraZeneca (Macclesfield, England).
Articles by Graham Illing
Advertisement
Latest Updated Articles
Drug Substance Starting Material SelectionPublished: December 2nd 2008 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
AI and Human Collaboration Essential for Bio/pharma Innovation
4
Why Sound Science Is Pharma's Best Defense Against Regulatory Shifts
5
